EX-99.1 2 ex033125991pressrelease.htm EX-99.1 Document
Exhibit 99.1
Performant Healthcare, Inc. Announces Financial Results for First Quarter 2025
Plantation, FL., May 8, 2025 - Performant Healthcare, Inc. (Nasdaq: PHLT), a leading provider of healthcare payment integrity services, today reported the following financial results for its first quarter ended March 31, 2025:
First Quarter 2025 Financial Highlights
•Total revenue of $33.3 million, compared to total revenue of $27.3 million in the prior year period.
•Healthcare revenue of $33.2 million, compared to $25.8 million in the prior year period, an increase of approximately 29%.
•Net loss of $0.1 million, or $0.00 per diluted share, compared to net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period.
•Adjusted EBITDA of $3.3 million, compared to $(1.2) million in the prior year period.
•Adjusted net income was $1.2 million, or $0.02 per diluted share, compared to adjusted net loss of $3.0 million, or $(0.04) per diluted share, in the prior year period.
First Quarter 2025 Results
Total revenue in the first quarter of 2025 was $33.3 million, an increase of 22% from total revenue of $27.3 million in the prior year period. Healthcare revenue was $33.2 million in the first quarter of 2025, representing an increase of approximately 29% from $25.8 million in the prior year period. Claims-based services revenue in the first quarter of 2025 was $17.1 million, while revenue from eligibility-based services in the first quarter was $16.1 million, an increase of 38% and 20%, respectively, over the same prior year period.
“Our first quarter revenue and profitability exceeded expectations, underscoring our commitment to a results-driven healthcare strategy,” stated Simeon Kohl, CEO of Performant. "Our quarterly results highlight the demand for Performant’s services and the robustness of our business model. We saw solid growth across both government and commercial clients in the quarter with the majority of growth continuing to come from commercial clients. In the first quarter, we implemented 13 commercial programs, estimated to contribute between $4.5 million and $5.0 million in annualized revenue at steady state. Amid an uncertain political and healthcare environment, Performant is well-positioned to provide clients with certainty and savings. Our mission is unchanged, we are committed to reducing wasteful spend in the healthcare system and we are dedicated to delivering sustainable growth and profitable expansion for our shareholders."
Net loss for the first quarter was $0.1 million, or $0.00 per diluted share, compared to a net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period. Adjusted EBITDA for the first quarter was $3.3 million as compared to $(1.2) million in the prior year period. Adjusted net income for the first quarter was $1.2 million, or $0.02 per share on a diluted basis, compared to adjusted net loss of $3.0 million, or $(0.04) per diluted share, in the prior year period.
"The strong start to the year gives us confidence to increase full-year adjusted EBITDA and revenue guidance," said Rohit Ramchandani, Chief Financial Officer. "These solid first-quarter results are a testament to our commitment and execution of the strategy set forth in 2021 when we transitioned to a pure-play healthcare company. With commercial clients, our largest growth area, we continue to see strong momentum driven by solid performance, a healthy pipeline, successful implementations, and a growing backlog of new contract awards that have yet to fully scale. We expect to deliver 2025 healthcare revenues in the range of $133 million to $135 million and adjusted EBITDA in the range of $9 million to $10 million. This increase in guidance reflects our solid first-quarter results and our optimistic outlook for the remainder of the year," Ramchandani further commented.


Note Regarding Use of Non-GAAP Financial Measures
In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results” table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax, and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. In regard to forward looking non-GAAP guidance, we are not able to reconcile the forward-looking non-GAAP adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items. These items include, but are not limited to, impacts associated with interest expense, and depreciation and amortization expenses.
Earnings Conference Call
The Company will hold a conference call to discuss its first quarter 2025 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. To dial into the call you can dial 800-717-1738 or 646-307-1865.
A replay of the call will be available on the Company's website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 1176510. The telephonic replay will be available approximately three hours after the call, through May 15, 2025.
About Performant Healthcare, Inc.
Performant supports healthcare payers in identifying, preventing, and recovering waste and improper payments by leveraging advanced technology, analytics and proprietary data assets. Performant works with leading national and regional healthcare payers to provide eligibility-based, also known as coordination-of-benefits (COB) services, as well as claims-based services, which includes the audit and identification of improperly paid claims. Performant is a leading provider of these services in both government and commercial healthcare markets. Performant also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs designed to mitigate future instances of improper payments.
To learn more, please visit http://www.performanthealthcare.com


Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), adjusted EBITDA in 2025 and beyond, our commercial client growth strategy, and our estimated revenue from commercial programs implemented in the first quarter of 2025. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to generate revenue following long implementation periods associated with new customer contracts; the high level of revenue concentration among our largest customers; client relationships and the Company’s ability to maintain such client relationships; many of the Company’s customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes; anticipated trends and challenges in the Company’s business and competition in the markets in which it operates; the Company’s indebtedness and compliance, or failure to comply, with restrictive covenants in the Company’s credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company’s ability to hire and retain employees with specialized skills that are required for its healthcare business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company’s ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health pandemics such as COVID-19 on the Company’s business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company’s operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company’s third-party vendors and subcontractors; the adaptability of the Company’s technology platform to new markets and processes; the Company’s ability to invest in and utilize our data and analytics capabilities to expand its capabilities; the Company’s growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company’s ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company’s ability to comply with and adapt to industry regulations and compliance demands.
More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.
Contact Information
Jon Bozzuto
Investor Relations
925-960-4988
investors@performantcorp.com

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(In thousands, except par value amounts)
 March 31,
2025		December 31,
2024
 (Unaudited) 
Assets
Current assets:
Cash and cash equivalents$9,981 $9,292 
Trade accounts receivable, net of allowance for credit losses14,713 14,165 
Contract assets13,059 10,876 
Prepaid expenses and other current assets4,217 3,991 
Income tax receivable— 34 
Total current assets41,970 38,358 
Property, equipment, and software, net14,025 14,021 
Goodwill47,372 47,372 
Debt issuance costs359 416 
Right-of-use assets867 826 
Other assets772 781 
Total assets$105,365 $101,774 
Liabilities and Stockholders’ Equity
Current liabilities:
Accrued salaries and benefits10,699 8,502 
Accounts payable1,347 482 
Other current liabilities1,807 2,091 
Income taxes payable35 — 
Contract liabilities591 753 
Estimated liability for appeals and disputes543 517 
Deferred asset acquisition payments1,216 1,243 
Lease liabilities163 383 
Total current liabilities16,401 13,971 
Long-term loan payable8,000 8,000 
Deferred asset acquisition payments2,015 2,686 
Lease liabilities723 462 
Other liabilities94 156 
Total liabilities27,233 25,275 
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value. Authorized, 500,000 shares at March 31, 2025 and December 31, 2024 respectively; issued and outstanding 78,309 and 78,309 shares at March 31, 2025 and December 31, 2024, respectively
8 8 
Additional paid-in capital153,402 151,688 
Accumulated deficit(75,278)(75,197)
Total stockholders’ equity78,132 76,499 
Total liabilities and stockholders’ equity$105,365 $101,774 

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
 Three Months Ended  
March 31,
 20252024
Revenues$33,269 $27,334 
Operating expenses:
Salaries and benefits25,358 23,221 
Other operating expenses7,761 8,034 
Total operating expenses33,119 31,255 
Income (loss) from operations150 (3,921)
Interest expense(289)(186)
Interest income98 106 
Loss before provision for income taxes(41)(4,001)
Provision for income taxes40 16 
Net loss$(81)$(4,017)
Net loss per share
Basic$— $(0.05)
Diluted$— $(0.05)
Weighted average shares
Basic78,309 76,920 
Diluted78,309 76,920 

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 Three Months Ended  
March 31,
 20252024
Cash flows from operating activities:
Net loss$(81)$(4,017)
Adjustments to reconcile net loss to net cash provided by operating activities:
Loss on disposal of assets— 29 
Depreciation and amortization1,452 1,398 
Right-of-use assets amortization146 108 
Stock-based compensation1,714 957 
Interest expense from debt issuance costs56 58 
Interest accretion on deferred asset acquisition67 — 
Changes in operating assets and liabilities:
Trade accounts receivable(548)3,301 
Contract assets(2,183)(1,000)
Prepaid expenses and other current assets(226)(480)
Income tax receivable34 335 
Other assets3 325 
Accrued salaries and benefits2,197 (1,850)
Accounts payable865 1,424 
Contract liabilities and other current liabilities(446)(365)
Income taxes payable35 7 
Estimated liability for appeals and disputes26 (10)
Lease liabilities(146)(106)
Other liabilities (61)7 
Net cash provided by operating activities2,904 121 
Cash flows from investing activities:
Purchase of property, equipment, and software(1,450)(3,652)
Net cash used in investing activities(1,450)(3,652)
Cash flows from financing activities:
Debt issuance costs paid— (14)
Deferred asset acquisition payments made(765)— 
Net cash used in financing activities(765)(14)
Net increase (decrease) in cash and cash equivalents689 (3,545)
Cash and cash equivalents at beginning of period9,292 7,333 
Cash and cash equivalents at end of period$9,981 $3,788 
Non-cash investing activities:
Deferred asset acquisition payments$— $3,718 
Supplemental disclosures of cash flow information:
Cash paid (received) for income taxes$4 $(304)
Cash paid for interest$227 $127 

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
 Three Months Ended  
March 31,
 20252024
(in thousands)
Adjusted EBITDA:
Net income (loss)$(81)$(4,017)
Provision for income taxes40 16 
Interest expense (1)
289 186 
Interest income(98)(106)
Stock-based compensation1,714 957 
Depreciation and amortization1,452 1,398 
Severance expenses (3)
— 336 
Other6 — 
Adjusted EBITDA$3,322 $(1,230)
 Three Months Ended  
March 31,
 20252024
(in thousands)
Adjusted Net Income (Loss):
Net income (loss)$(81)$(4,017)
Stock-based compensation1,714 957 
Amortization of debt issuance costs (2)
63 58 
Severance expenses (3)
— 336 
Other6 — 
Tax adjustments (4)
(490)(372)
Adjusted net income (loss)$1,212 $(3,038)
Three Months Ended  
March 31,
20252024
(in thousands)
Adjusted Net Income (Loss) Per Diluted Share:
Net income (loss)$(81)$(4,017)
Plus: Adjustment items per reconciliation of adjusted net income (loss)1,293 979 
Adjusted net income (loss)$1,212 $(3,038)
Adjusted net income (loss) per diluted share$0.02 $(0.04)
Diluted average shares outstanding (5)
79,407 76,920 
(1)Primarily represents interest expense and amortization of debt issuance costs related to our Credit Agreement.
(2)Represents amortization of debt issuance costs related to our Credit Agreement.
(3)Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.
(4)Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
(5)While net loss for the three months ended March 31, 2025 is ($81), the computation of adjusted net income (loss) results in adjusted net income of $1,212. Therefore, the calculation of the adjusted net income (loss) per diluted share for the three months ended March 31, 2025 includes dilutive common share equivalents of 1,098 added to the basic weighted average shares of 78,309.

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES
Quarterly and Annual Revenues
(In thousands)
(Unaudited)
We are providing the following historical breakdown of the quarterly and annual revenue contributions under the contribution breakdowns of our healthcare revenue results for the three months ended March 31, 2025, and for the years ended December 31, 2024, 2023 and 2022:
Three Months Ended
March 31, 2025
Eligibility-based$16,082 
Claims-based17,104 
Healthcare Total33,186 
Customer Care / Outsourced Services83 
Total$33,269 
Three Months Ended
Year Ended
March 31, 2024June 30, 2024September 30, 2024December 31, 2024December 31, 2024
(in thousands)
Eligibility-based$13,388 $14,264 $16,070 $18,138 $61,860 
Claims-based12,412 13,661 14,217 16,141 56,431 
Healthcare Total25,800 27,925 30,287 34,279 118,291 
Customer Care / Outsourced Services1,534 1,437 1,232 487 4,690 
Total$27,334 $29,362 $31,519 $34,766 $122,981 
Three Months Ended
Year Ended
March 31, 2023June 30, 2023September 30, 2023December 31, 2023December 31, 2023
(in thousands)
Eligibility-based$12,480 $14,131 $18,165 $16,403 $61,179 
Claims-based10,412 9,798 10,325 14,730 45,265 
Healthcare Total22,892 23,929 28,490 31,133 106,444 
Recovery19 14 — — 33 
Customer Care / Outsourced Services2,818 1,542 1,472 1,434 7,266 
Total$25,729 $25,485 $29,962 $32,567 $113,743 
Three Months Ended
Year Ended
March 31, 2022June 30, 2022September 30, 2022December 31, 2022December 31, 2022
(in thousands)
Eligibility-based$14,214 $12,417 $13,142 $13,511 $53,284 
Claims-based9,150 9,339 10,377 12,516 41,382 
Healthcare Total23,364 21,756 23,519 26,027 94,666 
Recovery118 7 41 75 241 
Customer Care / Outsourced Services3,601 3,918 3,618 3,140 14,277 
Total$27,083 $25,681 $27,178 $29,242 $109,184